BioAtla announced a reduction of roughly 70% of its workforce as the antibody-focused biotech conducts a strategic review to explore potential sales, licensing or other transactions to maximize shareholder value. The company cited constrained cash resources and is maintaining employees needed for the review while trimming other functions. BioAtla’s pipeline includes conditionally active biologics (CAB) and ADC programs such as mecbotamab vedotin and BA3182; the firm previously reported encouraging survival signals in late‑stage soft‑tissue sarcoma cohorts. The workforce cut follows prior reductions and a special‑purpose vehicle financing earlier in the year, underscoring financing pressures for mid‑stage antibody developers.